A Randomized, Split-head Comparison Study of the Efficacy and Safety of Platelet-rich Fibrin and Platelet Rich Plasma in Female Pattern Hair Loss Patients : A Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Female Pattern Hair Loss
- Sponsor
- Siriraj Hospital
- Enrollment
- 10
- Locations
- 2
- Primary Endpoint
- Trichoscan
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this clinical trial is to compare between platelet-rich fibrin and platelet-rich plasma in female pattern hair loss . The main question[s] it aims to answer are:
-
efficacy between platelet-rich fibrin and platelet-rich plasma
-
safety between platelet-rich fibrin and platelet-rich plasma Participants will be divided into 2 side of treatment with composed of
- Platelet rich plasma
- Platelet rich fibrin
Detailed Description
Subject was treated both platelet-rich fibrin and platelet-rich plasma for 3 times which 1 month interval then will be followed up at 4 months and 6 months after last treatment
Investigators
Rattapon Thuangtong
Associate Professor
Siriraj Hospital
Eligibility Criteria
Inclusion Criteria
- •Age 20-55 years
- •Subject who was diagnosed with Female pattern hair loss in Ludwig Classification 2 (part width 2-4 centimeters) by Dermatologist
Exclusion Criteria
- •Pregnancy or Lactation subjects
- •Subject with history of platelet dysfunction, low platelet, anemia, cirrhosis, cancer, or immunocompromised host
- •Subject who are active smoking and alcoholism
- •Subject who has dermatitis, scar or infection at intervention area
- •Subject who has history of allergy to anesthesia drug
- •Subject who taking NSAIDs, Hormonal drug, anticoagulants drug
- •Subject who has psychiatric condition diagnosed by psychiatrist
- •Subject who are not allowed to take a photo
Outcomes
Primary Outcomes
Trichoscan
Time Frame: baseline(week0), 4 months after last treatment(week20), 6 months after last treatment(week28)
Average counts and density of hair per 1.5mm\^2
Secondary Outcomes
- Visual analog scale(baseline(week0), 1 month after first treatment(week4), 1 months after second treatment(week8))
- The 7-point of doctor subjective global assessment(baseline(week0),1 month after first treatment(week4), 1 months after second treatment(week8), 4 months after last treatment(week20), 6 months after last treatment(week28))
- The 7-point of patient subjective global assessment(baseline(week0),1 month after first treatment(week4), 1 months after second treatment(week8), 4 months after last treatment(week20), 6 months after last treatment(week28))